Jan 8, 2025 · BioHarvest Sciences Inc. (CSE:BHSC, NASDAQ:BHST) CEO Ilan Sobel has reflected on 2024 as “a year of transformation and growth” for the company. In a letter to shareholders, Sobel highlighted the launch of the company’s Contract Development and Manufacturing Organization (CDMO) Services division as “the most transformational change in 2024” for BioHarvest.

Jan 9, 2025 · Mesoblast Limited CEO Silviu Itescu joined Steve Darling from Proactive to share news the company has announced the U.S. Food and Drug Administration has approved remestemcel-L, now marketed under the brand name Ryoncil, as the first and only therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged two months and older, including adolescents.

Imugene Ltd (ASX:IMU, OTC:IUGNF) has launched a Phase 1b clinical trial at the Royal Prince Alfred Hospital in Sydney, dosing the first Australian patient with its allogeneic CAR T-cell therapy azer-cel (azercabtagene zapreleucel) treatment. The trial will focus on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one …

Jan 9, 2025 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

Dec 24, 2024 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

Nov 27, 2024 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

Jan 7, 2025 · The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

Nov 29, 2024 · Cancer treatment has long been dominated by traditional approaches such as surgery, radiation, and chemotherapy. But in recent years, a wave of innovation has emerged, driven by the promise of immunotherapies that harness the …

Jan 6, 2025 · About Oliver Haill. Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research.

Nov 6, 2024 · Kinross Gold Corporation (TSX:K) posted a strong financial quarter for Q3 2024, reporting $1.43 billion in revenue, buoyed by higher gold prices. The company outperformed expectations on production and cash costs, supported by strong output at key mines, including Paracatu and Fort Knox.